echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > CheckMate 078 study 3 years of data update efficacy duration of up to 20 months.

    CheckMate 078 study 3 years of data update efficacy duration of up to 20 months.

    • Last Update: 2020-10-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    CheckMate 078 Study CheckMate 078 Study is the first multi-center, randomized controlled clinical study of late NSCLC for second-line treatment of Chinese groups of immunosuppressants in East Asian populations, aimed at evaluating The safety and efficacy of Nivolumab and Dorsey in patients with stage III.b/IV EGFR-negative and ALC-negative NSCLC who showed disease progression after treatment with platinum-containing dual-drug chemotherapy.
    research is mainly conducted in China, with simultaneous research centers in Russia and Singapore.
    patients were randomly assigned 2:1 to receive navuliyu monoantigen (n-338) or dossythal therapy until the disease progressed or indulging in toxicity.
    the main common endpoints are compared to the two groups of total survival (OS), the secondary endpoints include objective mitigation rate (ORR), progression-free lifetime (PFS), to treatment failure time (TTF), subgroup efficacy (tissue type, PD-L1 expression, Chinese groups), safety and tolerance.
    at this year's CSCO Conference, checkMate-078's three-year follow-up results were officially announced.
    1. 1/5 compared to 1/8, Navuliyu single-anti-second-line drugs led more second-line treatment of lung cancer patients across 3 years CheckMate-078 three-year follow-up results show that Navuliyu single-resistant 3-year OS rate of 19%, significantly higher than 12% of the chemotherapy group, suggesting that nearly 1/5 second-line immunotherapy patients can survive at least 3 years, while patients with traditional second-line chemotherapy only 1/83 years of survival! The results were similar to the three-year benefits of a three-year study of CheckMate-017 and 057 based on global population data (17% vs 8%).
    in this updated total survival data, the mid-level OS of Navuliyu monoantigen was 11.9 months, significantly higher than the 9.5 months in the chemotherapy group (HR s 0.75, 95% CI 0.61-0.93), and the risk of death decreased by 25%! Consistent with global data (11.1:8.1, HR=0.68).
    shows once again that whether the patient is positive or negative for PD-L1, whether squamous or non-squamous, Navuliyu mono-anti-phase chemotherapy can bring the exact survival benefits to the whole population! In addition to survival benefits consistent with global data, ORR and PFS also show global consistency.
    orR was 19% to 20% for NSCLC patients worldwide, or 18% for CheckMate-078 studies, and 0.78 for PFS in CheckMate-078 studies compared to standard chemotherapy.
    2. "Divided Foreign Affairs": Once the treatment is effective and long-term effective, DoR forced 20 months in this release of data, in addition to the three-year OS rate, we are very surprised to see the therapeutic duration of DoR's ultra-high value.
    data showed that the median DoR in the Navuliyu monoantigroup was 19.4 months, three times as much as the 6.2 months in the traditional chemotherapy group, meaning that patients who benefited from immunotherapy were able to maintain a sustained and effective 20-month period of steady control of the disease.
    If you look at the proportion of people who benefit from follow-up each year, DoR in 1 year, 2 years and 3 years is 66%, 40% and 30% respectively, which means that nearly 1/3 of patients with Navuliyu monoantimmune effect remain valid for 3 years, and the immune long-acting properties are dazzling! CheckMate 078 Research Past Data Review CheckMate 078 results were first presented at the AACR 2018 Annual Meeting, with Professor Wu Yilong presenting the results of the overall population study, the first clinical oral report by a Chinese expert at the AACR Conference.
    results showed that the Navuliu single-anti-group significantly extended OS compared to the Dossytha group, with the two groups of mid-OSs at 12.0 and 9.6 months (HR-0.68; 97.7% CI:0.52-0.90; P-0.0006), respectively.
    based on the results of this study, Navuliyu monoantior was approved in Chinese mainland for second-line treatment of late-stage NSCLC, opening a new era of NSCLC immunotherapy in China.
    Then, at the 2018 First Asian Lung Cancer Congress (IASCL-ACLC), lead researcher Professor Wu Yilong published the results of the CheckMate 078 PROs analysis, which used the Lung Cancer Symptom Scale (LCSS) to assess the severity of lung cancer symptoms and their impact on overall quality of life, as well as the EQ-5D scale to assess the overall quality of life of patients.
    results are similar to checkMate 017/057 results, and Navuliyu monoanti-dosytha can significantly reduce the load of disease-related symptoms and improve the quality of life of patients.
    2019 CSCO Annual Meeting, CheckMate 078 study 2 years follow-up data published, combined with the main results of previous CheckMate 078 studies, showed that in Chinese groups of pre-treatment late NSCLC patients The Navuliyu monoantior increases OS survival benefits by 10% over 2 years compared to chemotherapy, and also brings more benefits to PFS, ORR, and DOR;
    CheckMate 078 is the first clinical study of PD-1 inhibitors initiated in China, with 90% of Chinese patients.
    As a researcher, Professor Lu said the study's Chinese subgroup analysis confirmed for the first time that the effectiveness and safety of Navuliyu monoantigen in groups Chinese were better than standard chemotherapy, with no significant difference between the East and the West.
    all patients with squamous and non-squamous cancer benefit from PD-L1 expression or not.
    data update provides strong evidence that Navuliyu monoantigen provides new treatment options and long-term survival benefits for patients with advanced NSCLC in China, and that lung cancer is expected to become a controlled chronic disease.
    source: 1. Wu Y-L, Lu S, Cheng Y, et al. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient People With WithTreated Advanced Non-Small Cell Cancer Lung: CheckMate 078 Randomized Phase IIIClinical Trial, Journal of Thoracic Oncology (2019), doi: 2. Borghaei H, Paz-Ares L Horn, L. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl JMed. 2015;373:1627-1639.3. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl JMed. 2015;373:123-135. 4. Lu S, et al. CSCO 2018. Nivolumab (nivo) vs Docetaxel (doce) in Chinese Patients (pts) With Previously Treated Advanced (adv) Non-Small Cell Cell Cancer NSCLC: Results of CheckMate078.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.